Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases currently without satisfactory therapeutic solutions. Pharnext has a first-in-class drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating, inherited peripheral neuropathy. PXT3003 benefits from orphan drug status in Europe and the United States.
Date
Total number of shares composing the share capital
April 30, 2024
1,304,086 (1)
(1) This table will be subject to a monthly update of (i) the number of shares issued from the convertible bond program announced on June 7, 2021, with Global Tech Opportunities 13, and (ii) the OBSA program announced on October 3, 2022 with Equitis Gestion (a management trust set up by Néovacs), detailed in follow-up tables available HERE
Stock Market
Euronext Growth Paris
Mnemo
ALPHA
Bloomberg
ALPHA/FR – Reuters: ALPHA.PA
ISIN Code
FR001400N1P4
Closing date
31 December
First day of trading
18 July 2016
Number of shares
See table above
Indices
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Liquidity contract
Kepler Cheuvreux
Eligible to PEA-PME (French fiscal advantage)
Share price
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Initiation of coverage report*
R&D Day 2020 Event report*
Report on PREMIER trial initiation*
Report on the Open-Label Phase III Extension Study of PXT3003*
R&D Day 2021 Event report*
Report on PREMIER trial completed recruitment*
Report on €12m new loan*
Corporate update note (June, 2022)*
Neovacs €2.5m loan*
First patient enrolled in PREMIER extension study*
Neovacs €20.7m funding*
Funding headroom to support PXT3003 progress*
Revised legal structure to offer operational stability*
Improving FY23 financial footing*
Potential licensing deals could add confidence*
* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.
Corporate presentation
Pharnext corporate presentation
General Meeting
General Meeting
General Meeting
General Meeting
General Meeting
General Meeting
General Meeting
General meeting
General meeting
General meeting
General meeting
General meeting
Letter to shareholders
Regulated Information